|By PR Newswire||
|August 7, 2014 02:54 PM EDT||
MIAMI, Aug. 7, 2014 /PRNewswire/ -- NextSource Biotechnology (NSB) is a leading specialty pharmaceutical manufacturer with a focus on identifying and developing the most viable pipeline of "matured" and "innovative drugs" in today's global healthcare market.
The product name change from Lomustine (CCNU) to GleostineTM represents the company's strategic initiative to re-launch and re-brand its product pipeline of matured and innovative drugs. The new GleostineTM product labeling will be visible in the healthcare market by the fourth quarter of 2014. Lomustine is currently available through all payer organizations nationwide – including both commercial and government providers of prescription drug coverage.
GleostineTM is a sole source FDA approved product, which is also accessible through NextSource CARES, NSB's patient assistance program. As a result of the company's extensive market access efforts, the continued use of unregulated compounded products or any other unapproved versions of GleostineTM, will continue to present an unnecessary risk to both healthcare providers and patients. NextSource Biotechnology is committed to providing the highest quality product with a consistent market supply.
"The re-branding of GleostineTM," said Robert DiCrisci, President, CEO of NextSource Biotechnology, "is the first of many product launches to come. As this initiative continues, we will expand our product line to ensure consistent availability to patients with critical medical need."
About NextSource Biotechnology: Established in 2010, NextSource Biotechnology is a leading specialty pharmaceutical manufacturer with a focus on identifying and developing the most viable pipeline of "Matured" and "Innovative drugs" in today's global healthcare market. NextSource partner, CordenPharma Latina is an expert contract manufacturer helping leading pharmaceutical and Biotechnology companies link their requirements for product success with their patients' healthier lives.
SOURCE NextSource Biotechnology
In today's uber-connected, consumer-centric, cloud-enabled, insights-driven, multi-device, global world, the focus of solutions has shifted from the product that is sold to the person who is buying the product or service. Enterprises have rebranded their business around the consumers of their products. The buyer is the person and the focus is not on the offering. The person is connected through multiple devices, wearables, at home, on the road, and in multiple locations, sometimes simultaneously...
Jul. 26, 2016 12:45 AM EDT Reads: 620
Jul. 26, 2016 12:00 AM EDT Reads: 2,136
Jul. 26, 2016 12:00 AM EDT Reads: 1,537
Jul. 25, 2016 11:15 PM EDT Reads: 1,308
Jul. 25, 2016 11:15 PM EDT Reads: 2,011
Jul. 25, 2016 11:00 PM EDT Reads: 1,023
Jul. 25, 2016 11:00 PM EDT Reads: 1,513
Jul. 25, 2016 10:45 PM EDT Reads: 1,299
Jul. 25, 2016 10:15 PM EDT Reads: 1,677
Jul. 25, 2016 10:15 PM EDT Reads: 1,920
Jul. 25, 2016 10:00 PM EDT Reads: 1,942
Jul. 25, 2016 10:00 PM EDT Reads: 2,502
Jul. 25, 2016 08:30 PM EDT Reads: 1,934
Jul. 25, 2016 08:15 PM EDT Reads: 242
Jul. 25, 2016 08:00 PM EDT Reads: 1,917